Eli Lilly and the company today
Eli Lilly and Company
- 52-week range
- $ 711.40
▼
$ 972.53
- Dividend yield
- 0.62%
- P/e ratio.
- 72.15
- Value is valuable
- $ 997.50
Eli Lilly and Company NYSE: Lly It is one of the two pharmaceutical actions standing for the passion for a drug reduction that influenced the stock market and the healthcare system. The shares showed good results in 2025, the total yield of 12% as of February 11 closed. This year he meaningfully participated in the growth of the action. FIRM profit and loss report from 4024 February 6. GLP-1 medicines sales are still hot.
But does this mean that a rally in Eli Lilly will probably continue? Below I will discuss the main points from the income report and management commentary. Then I will provide the prospects for the shares of the company.
Lilly results send shares above after resetting the leadership
On the first line, Lilly’s income increased by 45%, which became a rapid pace that corresponded to expectations. Earnings will be more than doubled by searching for analysts at 6%. Mounjaro and Zepbound, key medicines of the company, demonstrated a strong growth. Mounjaro and Zepbound contain the same drug, tirzepatide. Mounjaro helps to treat type 2 diabetes, while Zepbound is designed for obesity.
Mounjaro sales increased by 60% compared to the 4th quarter of 2023. Zepbound sales increased by 985% to $ 1.9 billion. Nevertheless, Q4 2023 was the first quarter of Zepbound for the recipe, which is a key cause of astronomical growth. Zepbound sales growth by 52% from 3 quarter of 2024 is still very impressive and provides a more fair idea of the growth of sales of the drug. Despite these rapid growth rates, Mounjaro and Zepbound sales have not reached the initial forecasts of analysts. The estimates of this release of income were dropped after the company issued a preliminary update on January 14. The press release led to the fact that the shares fell by 6%.
Lilly: Accepting the market share, and for that, good reasons
In general, these sales helped Lilly continue to reduce their gap with Novo Nordisk A/S NYSE: NVO In the Inertin Inertin analogues market. Incretin analogues include injection GLP-1S, oral GLP-1 and double agonists GLP-1/GIP. Lilly has been steadily gaining a market share in Novo Nordisk since May 2024. Now it controls almost 49% of the market, while Novo controls 51%. This is an improvement by 5% compared to Q4 2023.
Most of this increase in the market share is due to studies showing that Zepbound is more effective in creating weight loss than the competing drug Novo, Wegovy. The results of the highest line in the framework of the Phase 3B Surmount-5 study showed that Zepbound provided 47% more relative weight loss compared to Wegovy. Lilly was also able to fix the problems associated with not lags behind demand much faster than Novo, another, probably, contributed to the growth of the market share. NOVO still has its own list of drugs, Semaglutide, in the list of lack of products and medicines control controls (FDA), while the FDA deleted Lilly’s in October 2024.
What’s next for Lilly, and this is a purchase?
In general, Lilly has several key ways to continue to support and expand the expected growth in 2025. Firstly, the company now has production capacity to prevent a narrow place of sales. The management says that in the first half of 2025 he will be able to make 60% more thyrzepatide than in the same period of 2024. The company also awaits phase 3 that its drug for the oral cavity, Orforglipron. It awaits the results in Q2 for diabetes and in Q3 for obesity. Successful results will be huge.
Eli Lilly and Marketrank ™ Analysis of Promotions
- General market ™
- 97th percentile
- Analyst rating
- Moderate purchase
- Breaking/disadvantage
- 18.1% growth
- Short level of interest
- Healthy
- The power of dividends
- Strong
- Environmental assessment
- -2,25
- Mood news
- 1.33
- Insider trade
- N/a
- Professe Earnings growth
- 33.26%
See full analysis
The drug will probably cost much less than Tyrzepatide. This is because the tablets are easier to do and store than injections. This can significantly expand who can access innovative drugs. A recent study of the American journal of managed medical care showed that US -USA leaders consider high costs as the main barrier for coverage for innovative drugs. Lilly also estimates that from 20% to 25% in patients in the USA has fear over the needle. The form of drug tablets can expand the availability for these people.
In connection with the solution to the problems of proposal, Lilly plans to launch global access to Orforglipron “As soon as possible” in early 2026. In general, the possibility of enormous closest growth in Lilly shares largely depends on the results of Orforglipron. I will not assume how these results may be. I believe that Lilly’s success in creating the most effective approved drug for Incretin gives him a great advantage in this area. This supply is a long -term distribution. This can really succeed with other candidates for the injection, even if Orforglipron failed. This provides a long -term opportunity for the market, which some believe that they can reach $ 150 billion. Average Price purposes from analysts Wall -Strith You still see solid potential in shares of almost 15%.
Before considering Eli Lilly and the company, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … And Eli Lilly and the company were not on the list.
While Eli Lilly and the company currently has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Need to place your plan 401k or Roth Ira? Use these investigation strategies that have time -tested time to increase the monthly pension income that generates your shares portfolio.
Get this free report